# A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

> **NCT07081555** · PHASE1 · RECRUITING · sponsor: **Affibody** · enrollment: 21 (estimated)

## Conditions studied

- Metastatic Breast Cancer
- HER2 + Breast Cancer

## Interventions

- **DRUG:** [177Lu]Lu-ABY-271

## Key facts

- **NCT ID:** NCT07081555
- **Lead sponsor:** Affibody
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-06
- **Primary completion:** 2027-01-01
- **Final completion:** 2028-06-01
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07081555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07081555, "A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT07081555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*